TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04011059

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Wharton's jelly-derived mesenchymal cells
Description: Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Wharton's jelly-derived mesenchymal cells
Description: Revascularization surgery, placement of an extracellular matrix patch with WJ-MSCs cultured on the epicardial surface and injection of WJ-MSC around the infarcted zone.
Study: NCT02866617

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model
Study: NCT03592472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pazopanib
Description: All patients will receive pazopanib at a starting dose of 800 mg by mouth (p.o.) daily on Days 1 to 28 of each treatment cycle. Patients should be instructed to take their once- daily oral dose of pazopanib at the same time each morning. Each dose of pazopanib should be taken with an 8 oz/240 mL glass of water either 1 hour before or 2 hours after a meal. Patients should be instructed to swallow the tablets whole and not chew them.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abexinostat
Description: The starting dose and schedule of abexinostat will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of abexinostat should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The starting dose and schedule of abexinostat matching placebo will be 80 mg p.o. BID on Days 1 to 4, 8 to 11, and 15 to 18 of every 28-day cycle, 2 doses 4 hours apart. Each dose of placebo should be taken with an 8 oz/240 mL glass of water at least half an hour before meals or more than 2 hours after a meal and must be 4 hours apart. Patients should be instructed to swallow the tablets whole and not chew them.
Study: NCT02923375

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymoangioblast-derived mesenchymal stem cells
Description: The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymoangioblast-derived mesenchymal stem cells
Description: The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
Study: NCT04667819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate
Description: We usage a special type of anterior eye drug delivery system to conduct the transmission of sodium hyaluronate in dry eye patients.
Study: NCT04163549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Safe at Home
Description: Discussion-based intervention
Study: NCT03285646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Subcutaneous (SC) every 4 weeks (Q4W)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous (SC) every 4 weeks (Q4W)
Study: NCT03623828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apomorphine Hydrochloride 50Mg/10mL Prefilled Syringe
Description: Product administered using an external continuous subcutaneous infusion pump.
Study: NCT04709237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A control lens
Description: Participants were randomized to wear omafilcon A control soft contact lens for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A control lens
Description: Participants were randomized to wear omafilcon A control soft contact lens for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A control lens
Description: Participants were randomized to wear omafilcon A control soft contact lens for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 1
Description: Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 1
Description: Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 1
Description: Participants were randomized to wear omafilcon A test soft contact lens 1 for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 2
Description: Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 2
Description: Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: omafilcon A test lens 2
Description: Participants were randomized to wear omafilcon A test soft contact lens 2 for 10 days.
Study: NCT02237105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Description: Cognitive Behavioral Therapy
Study: NCT03847181

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Rivaroxaban at a dose of 15 or 20 mg once daily

Intervention type: DRUG
Intervention: Apixaban (Eliquis)
Description: Apixaban at a dose of 2.5 or 5 mg twice daily

Intervention type: DRUG
Intervention: Warfarin
Description: Warfarin dose as prescribed by medical practitioner
Study: NCT04048460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delivery of hearing healthcare through eAudiology application
Description: Participants will receive bilateral, behind-the-ear hearing aids as part of this study. The intervention will involve e-Audiology sessions following the initial hearing aid fitting and orientation. E-Audiology sessions will consist of hearing aid follow-up programming, troubleshooting, HAT assistance, and general help with hearing devices. E-Audiology sessions will take place over the course of approximately 6 weeks.
Study: NCT03724422

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: A dose of 500cGy will be delivered in 1 fraction to the isocenter. Radiation will be administered no later than 72 hours postoperatively
Study: NCT03285373

Intervention type: DRUG
Intervention: NOAC
Description: New Oral Anticoagulant
Study: NCT01344057

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seasonal Influenza Vaccine
Description: This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
Study: NCT01662869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluoruracil
Description: Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluoruracil
Description: Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study: NCT03284957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Pharmaceutical form: tablet
Study: NCT01534052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Oral
Study: NCT01662869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Folinic acid
Description: Participants will receive folinic acid 400 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onartuzumab
Description: Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
Study: NCT05655715

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy
Description: 8 Gray x 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: 1 mg/kg IV Q3W for four doses,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab Injection [Yervoy]
Description: 1 mg/kg IV Q3W for four doses,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab 3mg/kg IV Q3W for four doses, then then Nivolumab 480mg IV Q4W

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: From soft tissue metastases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsies
Description: From soft tissue metastases.
Study: NCT01662869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 85 mg/m\^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
Study: NCT00907894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDT600 (Telbivudine)
Description: LDT600 (Telbivudine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDT600 (Telbivudine)
Description: LDT600 (Telbivudine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDT600 (Telbivudine)
Description: LDT600 (Telbivudine)
Study: NCT00843791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: treatment with placebo for 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
Study: NCT02433834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI
Description: GP MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI
Description: GP MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI
Description: GP MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI
Description: GP MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycopyrronium MDI
Description: GP MDI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Serevent Diskus 50 μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02229877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 40 mg oral capsules administered twice daily for 8.5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant
Description: Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
Study: NCT00796965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7268
Description: Solution/Capsule, Oral, once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04186910

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: The control group will carry the Fitbit for the entire period of the recovery but will receive no feedback and will not have the app downloaded onto the telephone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback group
Description: The feedback group will carry the Fitbit for the entire period of the recovery and will receive daily feedback on amount of physical activity carried out and percentage completed of target behavior at the end of the day from an app downloaded on their telephone. The feedback group will also participate in weekly one hour meetings focused on enhancing behavioral strategies to increase self-efficacy and motivation. They will also have their fitbit data analyzed and an agreed upon target of daily activity level increase.
Study: NCT02246504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HIFU treatment
Study: NCT00910715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: doxycycline 100 mg bid, 10 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline
Description: doxycycline 100 mg bid, 15 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: control subjects without a history of Lyme borreliosis
Study: NCT03909776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
Study: NCT03458494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Participants will receive meals traditionally consumed in Mediterranean countries

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-fat diet
Description: Participants will receive meals with a low content of total fat.
Study: NCT03909776

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin was administered intravenously or intraarterially after adequate IV hydration. For IA infusion, cisplatin was given via insertion of a catheter percutaneously by using the Seldinger technique through the brachial or femoral artery under anesthesia and usually at 120 mg/m2 as a 3-h/6-h continuous infusion; while for IV administration, it was given at 100-120 mg/m2 as 6-h infusions.
Study: NCT03819868

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High cost
Description: Surfaces allocated to this group will be treated with a high-cost sealant (Fluroshield®, Dentsply, São Paulo, Brazil), according to the manufacturer's instructions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low Cost
Description: Surfaces allocated to this group will be treated with a low-cost sealant (Prevent®, FGM Produtos Odontológicos, Santa Catarina, Brazil), according to the manufacturer's instructions.
Study: NCT01993407

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Task Switching Training
Description: Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control Task
Description: Participants will complete four, one-hour training sessions in which they will perform a single task each session
Study: NCT03417674

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Meal replacement by formula diet, exercise stimulation, and telemedicine coaching.
Study: NCT01977625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
Study: NCT04176354

Intervention type: DRUG
Intervention: Palbociclib + an aromatase inhibitor
Description: Palbociclib + an aromatase inhibitor therapy

Intervention type: DRUG
Intervention: Palbociclib + Letrozole
Description: Palbociclib + Letrozole therapy
Study: NCT00384137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Immunosuppression
Study: NCT00451282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: stepped preventive care
Description: 2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
Study: NCT04176354

Intervention type: DRUG
Intervention: Letrozole
Description: Letrozole monotherapy
Study: NCT03785522

Intervention type: DRUG
Intervention: Insulin degludec
Description: Patients will be treated with commercially available Tresiba® in a pre-filled pen injector (FlexTouch®) according to routine clinical practice at the discretion of the study doctor and in accordance with the local label. The study doctor will determine the starting dose of Tresiba® as well as any dose adjustments thereafter.
Study: NCT01370629

Intervention type: DRUG
Intervention: Vernakalant
Description: Prescribed at the discretion of the physician in accordance with their usual practice
Study: NCT00006014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study: NCT03847532

Intervention type: GENETIC
Group type: OTHER
Intervention: Sanger sequencing method
Description: Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.

Intervention type: GENETIC
Group type: OTHER
Intervention: Sanger sequencing method
Description: Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.

Intervention type: GENETIC
Group type: OTHER
Intervention: Sanger sequencing method
Description: Amplification of the examined fragments of the MutYH gene was conducted using the PCR machine TP4-PCR-01-Tertsik (DNA-Technology, Russia) containing 25 μL of the reaction mixture: 0.1-1.0 μg genomic DNA; 0.25 μM of each original oligoprimer; 200 μM of each nucleosidetriphosphate; 1 U Taq polymerase; PCR buffer (500 mM Tris, 500 mM KCl, pH 8.74); 2.5 μL MgCl2 (25 mM)); deionized water; 20-30 μL of mineral oil. For MutYH gene analysis (Transcript ENST00000257430) Primer3 software (http:// frodo.wi.mit.edu/primer3/input.htm) was selected and 16 primer pairs. The variants of the primary structure in the obtained fragments were revealed using SSCP. DNA fragments containing electrophoretically identified variants were sequenced.
Study: NCT03962114

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B3
Description: capsules with niagen
Study: NCT01487018

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Navigation Surgery
Description: To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Surgery
Description: To compare with the experamental group.